In this context, mTOR inhibition by rapamycin —approved by the FDA for the prophylaxis of organ transplant rejection, cancer, and certain autoimmune diseases [75]— has been primarily associated with its effects on autophagy. The gene discussed is MTOR; the disease is cancer.